Clinical Trial Update: Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating oral metronomic capecitabine in combination with pyrotinib for HER2-positive metastatic breast cancer that has been treated wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tyvyt (Sintilimab)
• Xeloda (capecitabine)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING